Apricus Biosciences Receives Positive Nasdaq Listing Determination
(Thomson Reuters ONE) -
SAN DIEGO, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc.
(Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in
urology and rheumatology, today announced that on February 8, 2017, the Company
was notified that the Nasdaq Hearings Panel (the "Panel") has granted the
Company's request for continued listing on Nasdaq pursuant to an extension
through May 30, 2017, by which date the Company must evidence full compliance
with all applicable criteria for continued listing on The Nasdaq Capital Market,
including the $2.5 million stockholders' equity requirement. The Company is
diligently working to timely satisfy the terms of the Panel's decision.
About Apricus Biosciences, Inc.
Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus' commercial product,
Vitaros®*, for the treatment of erectile dysfunction, is approved in Canada and
certain countries in Europe, Latin America and the Middle East and is being
commercialized in certain countries in Europe and the Middle East. In September
2015, Apricus in-licensed the U.S. development and commercialization rights for
Vitaros from Allergan. Apricus' marketing partners for Vitaros include Recordati
Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring
Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis
Pharmaceuticals Ltd. Apricus currently has one active product candidate,
RayVa(TM), its product candidate for the treatment of the circulatory disorder
Raynaud's phenomenon.
For further information on Apricus, visit http://www.apricusbio.com.
*Vitaros® is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act, as amended. Statements in this report
that are not purely historical are forward-looking statements. Such forward-
looking statements include, among other things: whether the Company can
demonstrate compliance with the Nasdaq's continue listing rules, including with
respect to stockholders' equity requirement. Actual results could differ from
those projected in any forward-looking statements due to a variety of reasons
that are outside of the Company's control, including, but not limited to: the
Company's ability to carry out its plan to regain compliance with the continued
listing requirements; risks associated with the Panel's ability to to delist the
stock prior to expiration of the extension period; and other risks identified by
the Company in its reports filed with the Securities and Exchange Commission
("SEC"). These forward-looking statements are made as of the date of this press
release, and the Company assumes no obligation to update the forward-looking
statements, or to update the reasons why actual results could differ from those
projected in the forward-looking statements. Readers are urged to read the risk
factors set forth in the Company's most recent annual report on Form 10-K,
subsequent quarterly reports filed on Form 10-Q, and other filings made with the
SEC. Copies of these reports are available from the SEC's website at www.sec.gov
or without charge from the Company.
CONTACT:
Matthew Beck
mbeck(at)troutgroup.com
The Trout Group
(646) 378-2933
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Apricus Biosciences, Inc. via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 09.02.2017 - 12:00 Uhr
Sprache: Deutsch
News-ID 523189
Anzahl Zeichen: 4418
contact information:
Town:
SAN DIEGO
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 165 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Apricus Biosciences Receives Positive Nasdaq Listing Determination"
steht unter der journalistisch-redaktionellen Verantwortung von
Apricus Biosciences, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
